• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Menopausal Disorders - Pipeline Review, H2 2011 - Product Image

Menopausal Disorders - Pipeline Review, H2 2011

  • Published: October 2011
  • 139 pages
  • Global Markets Direct

Menopausal Disorders - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Menopausal Disorders - Pipeline Review, H2 2011', provides an overview of the Menopausal Disorders therapeutic pipeline. This report provides information on the therapeutic development for Menopausal Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Disorders. 'Menopausal Disorders - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Menopausal Disorders.
- A review of the Menopausal Disorders products under development by companies and universities/research READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Menopausal Disorders Overview
Therapeutics Development
An Overview of Pipeline Products for Menopausal Disorders
Menopausal Disorders Therapeutics under Development by Companies
Menopausal Disorders Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Menopausal Disorders Therapeutics - Products under Development by Companies
Menopausal Disorders Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Menopausal Disorders Therapeutics Development
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Merck & Co., Inc.
Ablynx
Novartis AG
Arkopharma SA
Chiesi Farmaceutici SpA
Depomed, Inc.
GTx, Inc.
Japan Tobacco Inc.
Noven Pharmaceuticals, Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Bayer AG
Zosano Pharma, Inc.
Osteologix, Inc.
Paladin Labs Inc.
Bionovo, Inc.
Unigene Laboratories, Inc.
Uni-Bio Science Group Ltd.
Acceleron Pharma, Inc.
EffRx, Inc.
Radius Health, Inc.
Meditrina Pharmaceuticals, Inc.
Lipocine Inc.
Tarsa Therapeutics, Inc.
Pherin Pharmaceuticals, Inc.
Ausio Pharmaceuticals, LLC
Menopausal Disorders - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMG 785 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Odanacatib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Serada - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesafem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACE-011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Danggui Buxue Tang - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Estradiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BA058 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Phyto Soya Vaginal Gel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Denosumab + Alendronate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PTH 1-34 + Fluoride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PTH 1-34 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluoride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Calcitonin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Angeliq low-low - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY86-5310 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PH80-HF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nelfinavir + NRTIs + Estradiol + Medroxyprogesterone acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UNI-PH (1-34) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LPCN 1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Menopausal Disorders Therapeutics – Drug Profile Updates
Menopausal Disorders Therapeutics - Discontinued Products
Menopausal Disorders - Featured News
Sep 19, 2011: Merck Announces Presentation Of New Data On Odanacatib Phase III Investigational Cat-K Inhibitor For Osteoporosis At Annual Meeting Of American Society For Bone And Mineral Research
Sep 18, 2011: Tarsa Therapeutics Presents Positive Efficacy And Safety Data Comparing Oral Calcitonin To Nasal Calcitonin And Placebo In Phase III Osteoporosis Treatment Trial
Sep 17, 2011: Amgen Announces Prolia Phase II Extension Study Showed Continued Increase In Bone Mineral Density Over Eight Years Of Treatment
Aug 30, 2011: Bionovo Announces Positive Results From Tolerability Trial Of Menerba For Menopausal Hot Flashes
Aug 18, 2011: Amgen To Present Data From Prolia Studies At American Society For Bone And Mineral Research Meeting
Jul 25, 2011: Bionovo Announces Successful Completion Of Animal Toxicology Studies For MF101
Jul 12, 2011: Tarsa Therapeutics Advances Oral Calcitonin For Treatment And Prevention Of Postmenopausal Osteoporosis
Jun 17, 2011: Emisphere Receives Notice Of Results From Collaborator's Proof Of Concept Study For Oral PTH For Treatment Of Postmenopausal Osteoporosis
Jun 02, 2011: Bionovo To Present Data From Phase II Clinical Trial Of Menerba For Postmenopausal Vasomotor Symptoms At World Congress On Menopause
May 25, 2011: Ablynx To Present Clinical Data On Anti-RANKL Nanobody, ALX-0141 At Annual European Congress Of Rheumatology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos